Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:26
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [41] Determination of Vatiquinone Drug-Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Lee, Lucy
    Okudaira, Noriko
    Murase, Katsuyuki
    Kong, Ronald
    Jones, Hannah M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (02): : 160 - 169
  • [42] Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example
    Chen, Yuan
    Zhu, Rui
    Ma, Fang
    Mao, Jialin
    Chen, Eugene C.
    Choo, Edna F.
    Sahasranaman, Srikumar
    Liu, Lichuan
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (09) : 420 - 430
  • [43] Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Medi-ated Drug Absorption, Clearance and Drug-drug Interactions
    Taskar, Kunal S.
    Harada, Isobel
    Alluri, Ravindra, V
    CURRENT DRUG METABOLISM, 2021, 22 (07) : 523 - 531
  • [44] Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
    Park, Min-Ho
    Shin, Seok-Ho
    Byeon, Jin-Ju
    Lee, Gwan-Ho
    Yu, Byung-Yong
    Shin, Young G.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (01): : 107 - 115
  • [45] Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
    Jee Sun Min
    Soo Kyung Bae
    Archives of Pharmacal Research, 2017, 40 : 1356 - 1379
  • [46] Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
    Cohen-Rabbie, Sarit
    Zhou, Li
    Vishwanathan, Karthick
    Wild, Martin
    Xu, Sherrie
    Freshwater, Tomoko
    Jain, Lokesh
    Schalkwijk, Stein
    Tomkinson, Helen
    Zhou, Diansong
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (11): : 1493 - 1504
  • [47] The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant
    Saldanha, Leonor
    Vale, Nuno
    PHARMACEUTICS, 2023, 15 (09)
  • [48] Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
    Liu, Hongrui
    Yu, Yiqun
    Guo, Nan
    Wang, Xiaojuan
    Han, Bing
    Xiang, Xiaoqiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
    Lin, Louis
    Wong, Harvey
    PHARMACEUTICS, 2017, 9 (04)
  • [50] Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
    Arian Emami Riedmaier
    Kevin DeMent
    James Huckle
    Phil Bransford
    Cordula Stillhart
    Richard Lloyd
    Ravindra Alluri
    Sumit Basu
    Yuan Chen
    Varsha Dhamankar
    Stephanie Dodd
    Priyanka Kulkarni
    Andrés Olivares-Morales
    Chi-Chi Peng
    Xavier Pepin
    Xiaojun Ren
    Thuy Tran
    Christophe Tistaert
    Tycho Heimbach
    Filippos Kesisoglou
    Christian Wagner
    Neil Parrott
    The AAPS Journal, 23